5 news items
Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $13
PASG
15 May 24
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $14 to $13.
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
PASG
14 May 24
, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat
Canaccord Genuity Reiterates Buy on Passage Bio, Maintains $14 Price Target
PASG
5 Mar 24
Canaccord Genuity analyst Whitney Ijem reiterates Passage Bio (NASDAQ:PASG) with a Buy and maintains $14 price target.
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
PASG
4 Mar 24
designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative
Passage Bio to Participate in Upcoming Investor Conferences
PASG
27 Feb 24
with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology
- Prev
- 1
- Next